RCS - N4 Pharma PLC - N4 Pharma Launches New Interactive Investor Hub

N4 PharmaAnnouncement

30/11/2023 09:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231130:nRSd1106Va&default-theme=true

RNS Number : 1106V  N4 Pharma PLC  30 November 2023

Reach - Non-Regulatory

 

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

N4 Pharma Launches New Interactive Investor Hub

Company to provide shareholders with a more proactive way of communication and
enquiry support

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, announces
the launch of the N4 Pharma Interactive Investor Hub. For both existing and
prospective shareholders, the new Investor Hub brings all N4 Pharma content
into a single integrated platform to better inform and engage with investors
and stakeholders, including:

●     regulatory announcements

●     annual and interim reports

●     corporate presentations

●     company information

●     interviews with the Company's directors

●     corporate research on N4 Pharma

 

Investor Hub also provides an interactive online experience allowing Company's
stakeholders to comment on and ask the N4 Pharma team questions via a portal
which will be monitored.

 

To sign up for the N4 Pharma Investor Hub:

1.    Visit investors.n4pharma.com (https://investors.n4pharma.com/) .

2.    Follow the prompts to sign up for an investor hub account.

3.    Complete your account profile.

 

N4 Pharma's CEO and Founder, Nigel Theobald commented:

 

"At N4 Pharma, we have always encouraged our shareholders to engage with us.
We see Investor Hub as an effective platform upon which to further enable our
shareholders, and potential shareholders to interact with N4 Pharma. Investor
Hub will give us a platform to collate all our video material, information and
insights about our activities and plans in one place. We encourage our
stakeholders to trial Investor Hub and to provide feedback."

 

 

 

For more information please contact:

 

 N4 Pharma plc                                                Via IFC Advisory

 Nigel Theobald, CEO

 Luke Cairns, Executive Director
 SP Angel Corporate Finance LLP                               Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                        Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope
 IFC Advisory Ltd                                             Tel: +44(0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen
 InvestorHub                                                  Sign up at investors.n4pharma.com (https://investors.n4pharma.com/)

 Engage with us directly at N4 Pharma Investor Hub

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel
antigens in these fields to use Nuvec® as the delivery vehicle for these
antigens. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at www.investors.n4pharma.com
(http://www.investors.n4pharma.com) .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABLBATMTITBIJ